To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Repeated administration of intravenous immunoglobulin (IVIG) to improve the course of multiple sclerosis (MS) has now been tested in almost all stages of the disease, although to a variable extent and with various study designs. To date, two clinical trials have tested the effects of IVIG on progressive forms of MS. The efficacy of IVIG has been explored in several stages and settings of MS ranging from attempts to ameliorate the acute attack via investigations on the effects of long term immunomodulation to attempts of restoration of fixed deficits. Due to the good tolerability of IVIG, it has been recommended as a possible means to lessen disease activity that may be seen after delivery in some MS patients. The side effects observed at lower dosages of IVIG have been uniformly minor and consisted primarily of headaches, malaise, or a transient rash.
Email your librarian or administrator to recommend adding this to your organisation's collection.